# Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)

> **NCT02829151** · PHASE4 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 390 (estimated)

## Conditions studied

- Critical Limb Ischemia

## Interventions

- **DRUG:** Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )
- **DRUG:** Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel
- **DRUG:** Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol

## Key facts

- **NCT ID:** NCT02829151
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-21
- **Primary completion:** 2021-10
- **Final completion:** 2021-10
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2019-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02829151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02829151, "Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02829151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*